Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study.

Autor:	Nagaraj G; Loma Linda University Cancer Center, Loma Linda, United States., Vinayak S; Fred Hutchinson Cancer Research Center, Seattle, United States.; University of Washington, Seattle, United States.; Seattle Cancer Care Alliance, Seattle, United States., Khaki AR; Stanford University, Palo Alto, United States., Sun T; Vanderbilt University Medical Center, Nashville, United States., Kuderer NM; University of Washington, Seattle, United States.; Advanced Cancer Research Group, Kirkland, United States., Aboulafia DM; Virginia Mason Cancer Institute, Seattle, United States., Acoba JD; University of Hawaii Cancer Center, Honolulu, United States., Awosika J; University of Cincinnati Cancer Center, Cincinnati, United States., Bakouny Z; Dana-Farber Cancer Institute, Boston, United States., Balmaceda NB; The University of Kansas Cancer Center, Kansas City, United States., Bao T; Memorial Sloan Kettering Cancer Center, New York, United States., Bashir B; Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, United States., Berg S; Loyola University Medical Center, Maywood, United States., Bilen MA; Winship Cancer Institute, Emory University, Atlanta, United States., Bindal P; Beth Israel Deaconess Medical Center, Boston, United States., Blau S; Northwest Medical Specialties, Tacoma, United States., Bodin BE; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, United States., Borno HT; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States., Castellano C; Winship Cancer Institute, Emory University, Atlanta, United States., Choi H; University of Hawaii Cancer Center, Honolulu, United States., Deeken J; Inova Schar Cancer Institute, Fairfax, United States., Desai A; Mayo Clinic, Rochester, United States., Edwin N; ThedaCare Cancer Care, Appleton, United States., Feldman LE; University of Illinois Hospital & Health Sciences System, Chicago, United States., Flora DB; St. Elizabeth Healthcare, Edgewood, United States., Friese CR; Rogel Cancer Center, University of Michigan-Ann Arbor, Ann Arbor, United States., Galsky MD; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States., Gonzalez CJ; Rogel Cancer Center, University of Michigan-Ann Arbor, Ann Arbor, United States., Grivas P; Fred Hutchinson Cancer Research Center, Seattle, United States.; University of Washington, Seattle, United States.; Seattle Cancer Care Alliance, Seattle, United States., Gupta S; Cleveland Clinic, Cleveland, United States., Haynam M; The Ohio State University Comprehensive Cancer Center, Columbus, United States., Heilman H; University of Cincinnati Cancer Center, Cincinnati, United States., Hershman DL; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, United States., Hwang C; Henry Ford Cancer Institute, Henry Ford Hospital, Detroit, United States., Jani C; Mount Auburn Hospital, Cambridge, United States., Jhawar SR; The Ohio State University Comprehensive Cancer Center, Columbus, United States., Joshi M; Penn State Health St Joseph Cancer Center, Reading, United States., Kaklamani V; Mays Cancer Center, The University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, United States., Klein EJ; Lifespan Cancer Institute, Brown University, Providence, United States., Knox N; Stritch School of Medicine, Loyola University, Maywood, United States., Koshkin VS; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States., Kulkarni AA; Masonic Cancer Center, University of Minnesota, Minneapolis, United States., Kwon DH; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States., Labaki C; Dana-Farber Cancer Institute, Boston, United States., Lammers PE; Baptist Cancer Center, Memphis, United States., Lathrop KI; Mays Cancer Center, The University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, United States., Lewis MA; Intermountain Healthcare, Salt Lake City, United States., Li X; Vanderbilt University Medical Center, Nashville, United States., Lopes GL; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, United States., Lyman GH; Fred Hutchinson Cancer Research Center, Seattle, United States.; University of Washington, Seattle, United States.; Seattle Cancer Care Alliance, Seattle, United States., Makower DF; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, United States., Mansoor AH; Kaiser Permanente Northwest, Portland, United States., Markham MJ; Division of Hematology and Oncology, University of Florida Health Cancer Center, Gainesville, United States., Mashru SH; Kaiser Permanente Northwest, Portland, United States., McKay RR; Moores Cancer Center, University of California, San Diego, San Diego, United States., Messing I; Division of Radiation Oncology, George Washington University, Washington, United States., Mico V; Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, United States., Nadkarni R; Hartford HealthCare Cancer Institute, Hartford, United States., Namburi S; Northwest Medical Specialties, Tacoma, United States., Nguyen RH; University of Illinois Hospital & Health Sciences System, Chicago, United States., Nonato TK; Moores Cancer Center, University of California, San Diego, San Diego, United States., O'Connor TL; Roswell Park Comprehensive Cancer Center, Buffalo, United States., Panagiotou OA; Lifespan Cancer Institute, Brown University, Providence, United States., Park K; Loma Linda University Cancer Center, Loma Linda, United States., Patel JM; Beth Israel Deaconess Medical Center, Boston, United States., Patel KG; UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, United States., Peppercorn J; Massachusetts General Hospital, Boston, United States., Polimera H; Penn State Health St Joseph Cancer Center, Reading, United States., Puc M; Virtua Health, Marlton, United States., Rao YJ; Division of Radiation Oncology, George Washington University, Washington, United States., Razavi P; Moores Cancer Center, University of California, San Diego, San Diego, United States., Reid SA; Vanderbilt University Medical Center, Nashville, United States., Riess JW; UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, United States., Rivera DR; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, United States., Robson M; Memorial Sloan Kettering Cancer Center, New York, United States., Rose SJ; Carl & Dorothy Bennett Cancer Center, Stamford Hospital, Stamford, United States., Russ AD; Division of Hematology and Oncology, University of Florida Health Cancer Center, Gainesville, United States., Schapira L; Stanford University, Palo Alto, United States., Shah PK; Mays Cancer Center, The University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, United States., Shanahan MK; METAvivor, Annapolis, United States., Shapiro LC; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, United States., Smits M; ThedaCare Cancer Care, Appleton, United States., Stover DG; The Ohio State University Comprehensive Cancer Center, Columbus, United States., Streckfuss M; Aurora Cancer Care, Advocate Aurora Health, Milwaukee, United States., Tachiki L; Fred Hutchinson Cancer Research Center, Seattle, United States.; University of Washington, Seattle, United States.; Seattle Cancer Care Alliance, Seattle, United States., Thompson MA; Aurora Cancer Care, Advocate Aurora Health, Milwaukee, United States., Tolaney SM; Dana-Farber Cancer Institute, Boston, United States., Weissmann LB; Mount Auburn Hospital, Cambridge, United States., Wilson G; Masonic Cancer Center, University of Minnesota, Minneapolis, United States., Wotman MT; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States., Wulff-Burchfield EM; The University of Kansas Cancer Center, Kansas City, United States., Mishra S; Vanderbilt University Medical Center, Nashville, United States., French B; Vanderbilt University Medical Center, Nashville, United States., Warner JL; Vanderbilt University Medical Center, Nashville, United States., Lustberg MB; Yale Cancer Center, Yale University School of Medicine, New Haven, United States., Accordino MK; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, United States., Shah DP; Mays Cancer Center, The University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, United States.
Jazyk:	angličtina
Zdroj:	ELife [Elife] 2023 Oct 17; Vol. 12. Date of Electronic Publication: 2023 Oct 17.
DOI:	10.7554/eLife.82618
Abstrakt:	Background: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods: This is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with COVID-19 severity. Results: 1383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years, and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR per decade, 1.48 [95% CI, 1.32-1.67]); Black patients (aOR 1.74; 95 CI 1.24-2.45), Asian Americans and Pacific Islander patients (aOR 3.40; 95 CI 1.70-6.79) and Other (aOR 2.97; 95 CI 1.71-5.17) racial/ethnic groups; worse ECOG performance status (ECOG PS ≥2: aOR, 7.78 [95% CI, 4.83-12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63-3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20-2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66-3.04]); and active and progressing cancer (aOR, 12.5 [95% CI, 6.89-22.6]). Hispanic ethnicity, timing, and type of anti-cancer therapy modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and hospitalization rate for the entire cohort was 9% and 37%, respectively however, it varied according to the BC disease status. Conclusions: Using one of the largest registries on cancer and COVID-19, we identified patient and BC-related factors associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic patients experienced worse outcomes compared to non-Hispanic White patients. Funding: This study was partly supported by National Cancer Institute grant number P30 CA068485 to Tianyi Sun, Sanjay Mishra, Benjamin French, Jeremy L Warner; P30-CA046592 to Christopher R Friese; P30 CA023100 for Rana R McKay; P30-CA054174 for Pankil K Shah and Dimpy P Shah; KL2 TR002646 for Pankil Shah and the American Cancer Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE) and P30-CA054174 for Dimpy P Shah. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. Clinical Trial Number: CCC19 registry is registered on ClinicalTrials.gov, NCT04354701. Competing Interests: GN, SV, AK, TS, NK, DA, JA, JA, ZB, NB, TB, BB, SB, MB, PB, SB, BB, HB, CC, HC, JD, AD, NE, LF, DF, CF, MG, CG, PG, SG, MH, HH, DH, CH, CJ, SJ, MJ, VK, EK, NK, VK, AK, DK, CL, PL, KL, ML, XL, GL, GL, DM, AM, MM, SM, RM, IM, VM, RN, SN, RN, TN, TO, OP, KP, JP, KP, JP, HP, MP, YR, PR, SR, JR, DR, MR, SR, AR, LS, PS, MS, LS, MS, DS, MS, LT, MT, ST, LW, GW, MW, EW, SM, BF, JW, ML, MA, DS No competing interests declared
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu